Skip to main content
Top
Published in: Journal of Neurology 8/2023

Open Access 27-04-2023 | Magnetic Resonance Imaging | Original Communication

A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort

Authors: Maureen van Dam, Brigit A. de Jong, Eline A. J. Willemse, Ilse M. Nauta, Marijn Huiskamp, Martin Klein, Bastiaan Moraal, Sanne de Geus-Driessen, Jeroen J. G. Geurts, Bernard M. J. Uitdehaag, Charlotte E. Teunissen, Hanneke E. Hulst

Published in: Journal of Neurology | Issue 8/2023

Login to get access

Abstract

Background

Cognitive impairment in people with MS (PwMS) has primarily been investigated using conventional imaging markers or fluid biomarkers of neurodegeneration separately. However, the single use of these markers do only partially explain the large heterogeneity found in PwMS.

Objective

To investigate the use of multimodal (bio)markers: i.e., serum and cerebrospinal fluid (CSF) levels of neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) and conventional imaging markers in predicting cognitive functioning in PwMS.

Methods

Eighty-two PwMS (56 females, disease duration = 14 ± 9 years) underwent neuropsychological and neurological examination, structural magnetic resonance imaging, blood sampling and lumbar puncture. PwMS were classified as cognitively impaired (CI) if scoring ≥ 1.5SD below normative scores on ≥ 20% of test scores. Otherwise, PwMS were defined as cognitively preserved (CP). Association between fluid and imaging (bio)markers were investigated, as well as binary logistics regression to predict cognitive status. Finally, a multimodal marker was calculated using statistically important predictors of cognitive status.

Results

Only higher NfL levels (in serum and CSF) correlated with worse processing speed (r = − 0.286, p = 0.012 and r = − 0.364, p = 0.007, respectively). sNfL added unique variance in the prediction of cognitive status on top of grey matter volume (NGMV), p = 0.002). A multimodal marker of NGMV and sNfL yielded most promising results in predicting cognitive status (sensitivity = 85%, specificity = 58%).

Conclusion

Fluid and imaging (bio)markers reflect different aspects of neurodegeneration and cannot be used interchangeably as markers for cognitive functioning in PwMS. The use of a multimodal marker, i.e., the combination of grey matter volume and sNfL, seems most promising for detecting cognitive deficits in MS.
Appendix
Available only for authorised users
Literature
2.
go back to reference Eijlers AJ et al (2018) Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 141(9):2605–2618PubMed Eijlers AJ et al (2018) Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. Brain 141(9):2605–2618PubMed
3.
go back to reference Schoonheim MM et al (2021) Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. Mult Scler J 28(1):61–70CrossRef Schoonheim MM et al (2021) Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. Mult Scler J 28(1):61–70CrossRef
4.
go back to reference Di Filippo M, Portaccio E, Mancini A, Calabresi P (2018) Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci 19(10):599–609CrossRefPubMed Di Filippo M, Portaccio E, Mancini A, Calabresi P (2018) Multiple sclerosis and cognition: synaptic failure and network dysfunction. Nat Rev Neurosci 19(10):599–609CrossRefPubMed
5.
go back to reference Zivadinov R et al (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16(7):777–793CrossRefPubMed Zivadinov R et al (2016) Clinical relevance of brain atrophy assessment in multiple sclerosis. Implications for its use in a clinical routine. Expert Rev Neurother 16(7):777–793CrossRefPubMed
6.
go back to reference Stefano ND, Sormani MP (2020) Combining biomarkers to profile multiple sclerosis patients. Nat Rev Neurol 16(9):463–464CrossRefPubMed Stefano ND, Sormani MP (2020) Combining biomarkers to profile multiple sclerosis patients. Nat Rev Neurol 16(9):463–464CrossRefPubMed
7.
go back to reference Brummer T et al (2022) Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Commun 4(4):fcac153CrossRefPubMedPubMedCentral Brummer T et al (2022) Improved prediction of early cognitive impairment in multiple sclerosis combining blood and imaging biomarkers. Brain Commun 4(4):fcac153CrossRefPubMedPubMedCentral
8.
go back to reference Williams T et al (2022) Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: analysis from the MS-STAT randomised controlled trial. Mult Scler J 28(12):1913–1926CrossRef Williams T et al (2022) Serum neurofilament light and MRI predictors of cognitive decline in patients with secondary progressive multiple sclerosis: analysis from the MS-STAT randomised controlled trial. Mult Scler J 28(12):1913–1926CrossRef
9.
go back to reference Teunissen CE, Khalil M (2012) Neurofilaments as biomarkers in multiple sclerosis. Mult Scler J 18(5):552–556CrossRef Teunissen CE, Khalil M (2012) Neurofilaments as biomarkers in multiple sclerosis. Mult Scler J 18(5):552–556CrossRef
11.
go back to reference Ramani S, Berard JA, Walker LA (2021) The relationship between neurofilament light chain and cognition in neurological disorders: a scoping review. J Neurol Sci 420:117229CrossRefPubMed Ramani S, Berard JA, Walker LA (2021) The relationship between neurofilament light chain and cognition in neurological disorders: a scoping review. J Neurol Sci 420:117229CrossRefPubMed
12.
go back to reference Gaetani L et al (2019) Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. J Neurol 266(9):2157–2163CrossRefPubMed Gaetani L et al (2019) Cerebrospinal fluid neurofilament light chain tracks cognitive impairment in multiple sclerosis. J Neurol 266(9):2157–2163CrossRefPubMed
13.
go back to reference Högel H et al (2020) Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler J 26(2):210–219CrossRef Högel H et al (2020) Serum glial fibrillary acidic protein correlates with multiple sclerosis disease severity. Mult Scler J 26(2):210–219CrossRef
17.
go back to reference Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRefPubMed Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162–173CrossRefPubMed
18.
go back to reference Schagen S, Schmand B, de Sterke S, Lindeboom J (1997) Amsterdam short-term memory test: a new procedure for the detection of feigned memory deficits. J Clin Exp Neuropsychol 19(1):43–51CrossRefPubMed Schagen S, Schmand B, de Sterke S, Lindeboom J (1997) Amsterdam short-term memory test: a new procedure for the detection of feigned memory deficits. J Clin Exp Neuropsychol 19(1):43–51CrossRefPubMed
20.
go back to reference Verhage F (1964) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. Van Gorcum, Assen Verhage F (1964) Intelligentie en leeftijd: Onderzoek bij Nederlanders van twaalf tot zevenenzeventig jaar. Van Gorcum, Assen
21.
go back to reference Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1444CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1444CrossRefPubMed
22.
go back to reference Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc JINS 12(4):549CrossRefPubMed Benedict RH et al (2006) Validity of the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc JINS 12(4):549CrossRefPubMed
23.
go back to reference Smith A (1982) Symbol digit modalities test (SDMT) manual (revised) Western Psychological Services, Los Angeles Smith A (1982) Symbol digit modalities test (SDMT) manual (revised) Western Psychological Services, Los Angeles
24.
go back to reference Hammes J (1973) The STROOP color-word test: manual. Swets and Zeitlinger, Amsterdam Hammes J (1973) The STROOP color-word test: manual. Swets and Zeitlinger, Amsterdam
25.
go back to reference Mulder J, Dekker R, Dekker DH (1996) Verbale Leer- & Geheugen test: Handleiding [Verbal Learning & Memory Test: Manual]. Swets & Zeitlinger, Lisse Mulder J, Dekker R, Dekker DH (1996) Verbale Leer- & Geheugen test: Handleiding [Verbal Learning & Memory Test: Manual]. Swets & Zeitlinger, Lisse
26.
go back to reference Benedict RH, Schretlen D, Groninger L, Dobraski M, Shpritz B (1996) Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychol Assess 8(2):145CrossRef Benedict RH, Schretlen D, Groninger L, Dobraski M, Shpritz B (1996) Revision of the Brief Visuospatial Memory Test: Studies of normal performance, reliability, and validity. Psychol Assess 8(2):145CrossRef
27.
go back to reference Benton L, Hamsher K, Sivan A (1994) Controlled oral word association test, multilingual aphasia examination. AJA Associates, Iowa City Benton L, Hamsher K, Sivan A (1994) Controlled oral word association test, multilingual aphasia examination. AJA Associates, Iowa City
28.
go back to reference Parmenter BA, Testa SM, Schretlen DJ, Weinstock-Guttman B, Benedict RH (2010) The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 16(1):6–16CrossRefPubMed Parmenter BA, Testa SM, Schretlen DJ, Weinstock-Guttman B, Benedict RH (2010) The utility of regression-based norms in interpreting the minimal assessment of cognitive function in multiple sclerosis (MACFIMS). J Int Neuropsychol Soc 16(1):6–16CrossRefPubMed
29.
go back to reference Fischer M et al (2014) How reliable is the classification of cognitive impairment across different criteria in early and late stages of multiple sclerosis? J Neurol Sci 343(1–2):91–99CrossRefPubMed Fischer M et al (2014) How reliable is the classification of cognitive impairment across different criteria in early and late stages of multiple sclerosis? J Neurol Sci 343(1–2):91–99CrossRefPubMed
30.
go back to reference Benedict RH et al (2003) Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler J 9(1):95–101CrossRef Benedict RH et al (2003) Screening for multiple sclerosis cognitive impairment using a self-administered 15-item questionnaire. Mult Scler J 9(1):95–101CrossRef
32.
go back to reference Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G (1994) Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 38(5):383–392CrossRefPubMed Vercoulen JH, Swanink CM, Fennis JF, Galama JM, van der Meer JW, Bleijenberg G (1994) Dimensional assessment of chronic fatigue syndrome. J Psychosom Res 38(5):383–392CrossRefPubMed
33.
go back to reference Soldatos CR, Dikeos DG, Paparrigopoulos TJ (2000) Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 48(6):555–560CrossRefPubMed Soldatos CR, Dikeos DG, Paparrigopoulos TJ (2000) Athens Insomnia Scale: validation of an instrument based on ICD-10 criteria. J Psychosom Res 48(6):555–560CrossRefPubMed
35.
36.
go back to reference Kuhle J et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med (CCLM) 54(10):1655–1661CrossRefPubMed Kuhle J et al (2016) Comparison of three analytical platforms for quantification of the neurofilament light chain in blood samples: ELISA, electrochemiluminescence immunoassay and Simoa. Clin Chem Lab Med (CCLM) 54(10):1655–1661CrossRefPubMed
37.
go back to reference Hosmer DW Jr, Lemeshow S, Sturdivant RX (2013) Applied logistic regression. Wiley, New YorkCrossRef Hosmer DW Jr, Lemeshow S, Sturdivant RX (2013) Applied logistic regression. Wiley, New YorkCrossRef
42.
go back to reference Jakimovski D et al (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 6(9):1757–1770CrossRefPubMedPubMedCentral Jakimovski D et al (2019) Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study. Ann Clin Transl Neurol 6(9):1757–1770CrossRefPubMedPubMedCentral
43.
44.
go back to reference Ebenau JL et al (2022) Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology 98(13):e1315–e1326CrossRefPubMedPubMedCentral Ebenau JL et al (2022) Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive decline. Neurology 98(13):e1315–e1326CrossRefPubMedPubMedCentral
45.
go back to reference Cruz-Gomez ÁJ et al (2021) Cortical thickness and serum NfL explain cognitive dysfunction in newly diagnosed patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8(6):e1074CrossRefPubMedPubMedCentral Cruz-Gomez ÁJ et al (2021) Cortical thickness and serum NfL explain cognitive dysfunction in newly diagnosed patients with multiple sclerosis. Neurol Neuroimmunol Neuroinflamm 8(6):e1074CrossRefPubMedPubMedCentral
46.
go back to reference Kalb R et al (2018) Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler J 24(13):1665–1680CrossRef Kalb R et al (2018) Recommendations for cognitive screening and management in multiple sclerosis care. Mult Scler J 24(13):1665–1680CrossRef
Metadata
Title
A multimodal marker for cognitive functioning in multiple sclerosis: the role of NfL, GFAP and conventional MRI in predicting cognitive functioning in a prospective clinical cohort
Authors
Maureen van Dam
Brigit A. de Jong
Eline A. J. Willemse
Ilse M. Nauta
Marijn Huiskamp
Martin Klein
Bastiaan Moraal
Sanne de Geus-Driessen
Jeroen J. G. Geurts
Bernard M. J. Uitdehaag
Charlotte E. Teunissen
Hanneke E. Hulst
Publication date
27-04-2023
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 8/2023
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-023-11676-4

Other articles of this Issue 8/2023

Journal of Neurology 8/2023 Go to the issue